|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
WHO007582765 |
003 |
DE-627 |
005 |
20230425182945.0 |
007 |
cr uuu---uuuuu |
008 |
210512s2021 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)WHO007582765
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2020-005887-70-CZ
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)REMED
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomized controlled trial
|b Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomized controlled trial
|
264 |
|
1 |
|c 2021
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 11-01-2021, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: Acute respiratory distress syndrome (ARDS) associated with COVID-19 pneumonia;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 2
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 03. Mai
|
773 |
1 |
8 |
|g year:2021
|g day:03
|g month:05
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005887-70
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2021
|b 03
|c 05
|